PALI-2108

DRUG2 trials

Sponsors

Palisade Bio

Conditions

Fibrostenotic Crohn's DiseaseHealthy VolunteerUlcerative Colitis (UC)

Phase 1

Phase 1 Study Evaluating PALI-2108 in Healthy Volunteers and Ulcerative Colitis Patients.

CompletedNCT06663605

Palisade BioHealthy Volunteer, Ulcerative Colitis (UC)

Start: 2024-11-05End: 2025-08-07Updated: 2025-08-07

A Study of PALI-2108 in Healthy Volunteers, Patients With Ulcerative Colitis, and Patients With Fibrostenosing Crohn's Disease

Active, not recruitingNCT07428096

Palisade BioFibrostenotic Crohn's Disease

Start: 2025-10-17End: 2026-03-15Target: 6Updated: 2026-02-23

Related Papers

PALI-2108, A COLON TARGETED PDE4B INHIBITOR, RAPIDLY RESTORES IMMUNE-EPITHELIAL BALANCE IN ULCERATIVE COLITIS THROUGHGUT-SELECTIVE LYMPHOCYTE DEPLETION

Inflammatory Bowel Diseases2026-01-22